Transgene Sa · EURONEXT:TNG
Transgene Sa — Investor Presentation (June 2022)
47 slides from Transgene Sa's investor presentation, Jun 13, 2022
Slide 1: Virus Powered Immunotherapies against Solid Tumors
Virus Powered Immunotherapies against Solid Tumors Corporate Presentation June 13, 2022
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. There can be no guarantee that (i) the results of pre-clinical work and prior clinical trials will be
Slide 3: An Experienced Management Team
An Experienced Management Team Click to edit Master title style ÉRIC QUÉMÉNEUR, PHD HEDI BEN BRAHIM Executive VP Chief Executive Officer Chief Scientific Officer 20 YEARS EXPERIENCE 30+ YEARS EXPERIENCE ALESSANDRO RIVA Chairman Joined in March 2022 30+ YEARS EXPERIENCE MAUD BRANDELY, MD, STEVEN BLOO
Slide 4: Potential game changing approach to the treatment of solid tumors
Transgene – Potential game changing approach to the treatment of solid tumors Customized and Click to edit Master titleOff-The-Shelf style Cancer Immunotherapies Significant news flow in next 18 months including: 2 platforms 4 clinical-stage • TG4001 Ph.2 interim analysis in Q4 2022 for anogenital H
Slide 5: Our Expertise Translates into Two Unique Technology Platforms
Our Expertise Translates into Two Unique Technology Platforms Able Click toto editTarget Multiple Master title style Solid Tumors THERAPEUTIC VACCINE (MVA) Patient specific antigens selected to generate the optimal immune response Viral Immune T cell activation through multi-mechanisms vector • Prim
Slide 6: Multiple Opportunities to Transform Solid Tumor Therapy
Multiple Opportunities to Transform Solid Tumor Therapy Product Click to editTarget/transgene Master title style Indication Collaboration Preclinical Phase I Phase II Next step THERAPEUTIC VACCINE Anogenital HPV+ TG4001 HPV16 E6 – E7 cancers Interim analysis Q4 2022 Head and neck Additional Ph. I da
Slide 7: Transgene & AstraZeneca to Co-Develop Novel Invir.IO OVs
Transgene & AstraZeneca to Co-Develop 5 Novel Invir.IO™ OVs Click to edit Master title style Transgene and AstraZeneca entered into a collaboration and exclusive license option agreement in 2019 For 5 innovative Invir.IO™ based armed oncolytic immunotherapies Integrating one or more transgene(s) cho
Slide 8: TG4001: Potential to Transform Treatment of Anogenital HPV Positive Solid Tumors
TG4001 Potential to Transform the Treatment of Anogenital HPV Positive Solid Tumors Interim analysis expected in Q4 2022
Slide 9: TG4001 | Optimized Treatment for HPV-Positive Tumors
TG4001 | Optimized Treatment for HPV-Positive Tumors Potential to Address Click to edit Master title style All HPV Positive Cancers Ongoing Phase II trial MVA virus Anogenital HPV16-positive cancers E6 and E7 without liver metastasis HPV antigens 25,000 new pts/year Current SOC 1L platinum-based the
Slide 10: TG4001 | Phase Ib/II Data with Avelumab Presented at SITC 2020
TG4001 | Phase Ib/II Data of TG4001 with Avelumab Presented at SITC 2020 Promising Results, Click to edit Master Particularly in Patients without Liver Metastasis (NCT03260023) title style 34 heavily pretreated patients with metastatic HPV16+ cancer (oropharyngeal, anogenital) Compares favorably Ide
Slide 11: TG4001 | Randomized Controlled Phase II Trial
TG4001 | Randomized Controlled Phase II Trial Supported by Clinicians Trial to Enroll up to ~ 150 Patients (NCT03260023) Patients with HPV16-positive anogenital cancer incl. cervical, vulvar, vaginal, penile and anal cancers With recurrent/metastatic disease Treated in 1st line or in 2nd line (with
Slide 12: Individualized Neoantigen Vaccine
Individualized Neoantigen Vaccine Taking the Treatment of Each Patient’s Tumor to a New Level First positive data from the two Phase I trials one patient • one genome • one vaccine
Slide 13: TG4050 | An Individualized Neoantigen Vaccine
TG4050 | An Individualized Neoantigen Vaccine Combining Unique Capabilities Combines Bioengineering Click to edit Master title style and Digital Transformation 50% Click to play of development costs covered by NEC DATA PROCESSING, ARTIFICIAL INTELLIGENCE GENE EDITING MUTANOME & Selection of 30 Vacci
Slide 14: TG4050 - First Individualized Vaccine Based on myvac Technology
TG4050 - First Individualized Vaccine Based on the myvac® Technology 2Click ongoing clinical to edit Master trials title style TWO TRIALS DESIGNED TO PROVIDE FIRST EFFICACY DATA AND SUPERIOR IMMUNOGENICITY TG4050 monotherapy could address variety of solid tumors Moderately mutated tumors in patients
Slide 15: TG4050 | Ovarian Cancer Trial after Surgery and Adjuvant Chemotherapy
TG4050 | Ovarian Cancer Trial after Surgery and Adjuvant Chemotherapy Click to edit Master title style Complete response Clinical remission Asymptomatic relapse Approx. 80% of patients 12-month PFS CA-125 increase experience CR[1] of approx. 50%[1] or small lesions* Phase I Trial in up Surgery + Adj
Slide 16: First Patient Treated with TG4050 in Ovarian Cancer Trial
First Patient Treated with TG4050 in Ovarian Cancer Trial Normalization Click to edit Masteroftitle CA-125 style and ctDNA without Clinical Progression for 9 Months Relevant medical history Decline in ctDNA was concomitant 73-year-old female and treatments with CA-125 normalization and disease contr
Slide 17: Extremely Promising First Signals of Clinical Activity
Extremely Promising First Signals of Clinical Activity From Click to Repeated Injections edit Master title style of TG4050 as Monotherapy in Patients with Minimal Residual Disease Ovarian Cancer Trial As of mid-May 2022 Good safety profile No related SAEs Expected time of clinical progression[1] Pat
Slide 18: TG4050 | HPV-Negative Head and Neck Cancer Trial
TG4050 | HPV-Negative Head and Neck Cancer Trial after Surgery and Adjuvant Therapy Click to edit Master title style Arm A TG4050 is designed to INCREASE and EXTEND REMISSION period TG4050 Recurrence (single agent) Repeated injections Randomized Phase I Trial Surgery + Complete TG4050 + SOC Adjuvant
Slide 19: Extremely Promising First Signals of Clinical Activity: Head & Neck
Extremely Promising First Signals of Clinical Activity From Click to Repeated Injections edit Master title style of TG4050 as Monotherapy in Patients with Minimal Residual Disease Head & Neck Cancer Trial No related SAEs As of mid-May 2022 Good safety profile Arm A: TG4050 single agent All 8 treated
Slide 20: Unprecedented Rate of T Cell Response Against Tumor Specific Epitopes
Unprecedented Rate of T Cell Response Against Tumor Specific Epitopes Profound Remodelling Click to edit Master title style of Immune Cells Consistent with Anti Tumor Response Priming of innate immunity Immune differentiation during response to immunotherapies Differentiation of CD4 and CD8 Naïve Ef
Slide 21: TG4050 | Next Steps
TG4050 | Next Steps Click to edit Master title style Additional data to be These immune and presented at major scientific clinical data will serve congresses, incl. in H2 2022 to identify the most appropriate path to take TG4050 to Phase II and forward one patient • one genome • one vaccine 21
Slide 22: Our Unique Invir.IO Platform
Our Unique Invir.IO™ Platform Rapidly Generating Multiple Virus-Powered Off-the-Shelf Drug Candidates
Slide 23: Administered via IV, Oncolytic Viruses Could Be the Next Big Thing
Administered via the Intravenous Route (IV), Oncolytic Viruses Could Be the “Next Big Thing” Injectable Non-injectable lesions lesions Locally advanced cancers Metastatic cancers (e.g. SSCC, soft tissue sarcoma, (e.g. NSCLC, SCHNC, TNBC, melanoma melanoma wo visceral lesions) w visceral lesions) Wit
Slide 24: Invir.IO Oncolytic Viruses Are Designed to Address Most Cancer Indications
Invir.IO™ Oncolytic Viruses Are Designed to Address Most Cancer Indications Competitive Advantage of the Patented Backbone VVcopTK-RR- from Invir.IO™ Platform Safety and Selectivity Tumor eradication including metastases Multiple modes of action Patented TK-RR- deletion for enhanced tumor selectivit
Slide 25: TG6002 | Chemotherapy Produced Directly in the Tumor
TG6002 | Chemotherapy Produced Directly in the Tumor Ongoing Click to edit Phase I Trials Master title style assessing systemic routes of administration Oncolytic armed with Indication: 5-FU sensitive cancers FCU1 gene, prodrug Current SoC in 2L: bevacizumab + folfiri/folfox activator (3L: regorafen
Slide 26: TG6002 | Interim Phase I Data Presented at AACR and ESMO
TG6002 | Interim Phase I Data Presented at AACR and ESMO 2021 Clinical PoC Click to edit of title Master Feasibility of IV Route for our Patented VVcop TK-RR- Virus thestyle TG6002 replicates in tumor 5-FU is expressed in tumor Long-lasting expression tissue without sign of tissue in most of the of
Slide 27: BT-001 | Patented OV armed with anti-CTLA4 Ab + GM-CSF
BT-001 | Patented OV armed with anti-CTLA4 Ab + GM-CSF Ongoing Click to edit Phase I Trial Master title style Assessing IT* Route of Administration The right virus + payload Exciting preclinical data VVcopTK-RR- oncolytic armed with BioInvent’s potent anti-CTLA4 Ab + GM-CSF · Outstanding and long-la
Slide 28: BT-001 | Phase I/II Trial Starting in Europe
BT-001 | Phase I/II Trial Starting in Europe Leverage the IT* Click to edit Master title Route style to Accelerate Development with Anti-PD1 (NCT04725331) Repeated and Patients with ascending doses metastatic or of BT-001 IT* advanced injectable solid tumors such as: soft tissue sarcoma, Merkel cell
Slide 29: Invir.IO Pipeline Will Allow us to Generate Significant Value
Invir.IO™ Pipeline Will Allow us to Generate Significant Value Next Click toCandidates edit Master title are style Already in Preclinical Development Value provider and collaboration Highly initiator productive platform AstraZeneca collaboration: Backbone with development of new OVs unique propertie
Slide 30: Outlook
Outlook transgene
Slide 31: Company Funded to Deliver Multiple Value Generating Milestones
Company Funded to Deliver Multiple Value Generating Milestones Ownership €46.8 million in cash and cash equivalents As of March 31, 2022 as of March 31, 2022 In addition: Tasly BioPharmaceuticals shares valued at €18.9 million at the end of December 2021 62% Free float 38% • Listed on Euronext Paris
Slide 32: 2022 Upcoming Milestones
2022 Upcoming Milestones AClick to editLeader World Master title style in Virus-Powered Immunotherapies against Solid Tumors TG4001 HPV-positive cancers therapeutic MVA individualized neo-antigen VVcopTK-RR- multi-armed oncolytic vaccine therapeutic cancer vaccine viruses TG4001 TG4050 BT-001 Phase
Slide 33: Appendices
Ccpamecrane Appendices
Slide 34: Engineering viral vectors as immunotherapeutics
Engineering viral vectors as immunotherapeutics Turning Click to editfoes into Master friends title style Priming and activation Local induction of immuno- ③ ④ Trafficking of Viral-vector vaccine stimulatory pathways T-cells to tumors Antigen Expression of presentation cancer antigens ② Oncolytic ve
Slide 35: How Virus Powered Vaccines Treat Solid Tumors
How Virus Powered Vaccines Treat Solid Tumors Our vaccines Click to edit Masterinduce title style specific and strong immune response Local transgene Tumor cell killing expression and antigen processing CD8 Immune cell infiltration Cytotoxic activity of CD8 T cell Antigen spreading Danger signals An
Slide 36: Invir.IO Products Display Multiple Modes of Action in the Tumor Micro-Environment
Invir.IO™ Products Display Multiple Modes of Action in the Tumor Micro-Environment Armed oncolytics Click to edit designed to improve the treatment of primary and secondary tumors Master title style Immune system Local delivery of Tumor cell breakdown therapeutic ignition APC CD4 VV Payload expressi
Slide 37: Transgene Teams
Transgene Teams Board of Master Click to edit Directors title style Hedi Ben Brahim Alain Mérieux Marie Landel Philippe Archinard Laurence Espinasse CEO & Director Honorary Chairman Director Director Director Alessandro Riva Jean-Luc Bélingard Maya Said Jean-Yves Blay Benoît Habert Sandrine Flory Ch
Slide 38: Appendices: TG4050
Ccpamecrane Appendices TG4050
Slide 39: myvac | An Integrative Approach Capitalizing on Multiple Technologies
myvac® | An Integrative Approach Capitalizing on Multiple Cutting-Edge Technologies Taking the Click to edit Treatment Master title style of Each Patient to a New Level MVA Viral Vector: a Powerful Multiple Proprietary Innovative Technologies Platform for Vaccine Development Well-established safety
Slide 40: Appendices: TG4001
Ccpamecrane Appendices TG4001
Slide 41: TG4001 | Treatment Induced Long-Lasting Responses and Changes in Tumor Micro-Environment
TG4001 | Treatment Induced Long-Lasting Responses and Changes in Clickthe Tumor to edit Master titleMicro-Environment style Evolution of tumor size in patients without liver metastases TG4001 elicits strong, long-lasting and specific T-cell response against HPV16 E6 and E7 Treatment shifts « cold »
Slide 42: Significant Opportunity for TG4001 in Anogenital HPV16-Positive Cancers
Significant Opportunity for TG4001 in Anogenital HPV16-Positive Cancers HPV16 etiology Click to edit creates Master title style a significant market opportunity Incidence of anogenital HPV16 positive cancers w/o liver metastases Newly diagnosed patients with metastatic disease and patients with recu
Slide 43: Appendices: invir
Ccpamecrane Appendices invir®
Slide 44: Multiple Payloads | Deliver Significant Patient Benefits
Multiple Payloads | Deliver Significant Patient Benefits Local Click to payload edit Master delivery title style helps better neutralize the tumor in an effective and safe manner by limiting systemic exposure Targeted insertion of recombinant payload at selected loci in the Vaccinia genome Several I
Slide 45: TG6002 | Phase I/IIa Trial to Evaluate Intravenous Administration
TG6002 | Phase I/IIa Trial to Evaluate Intravenous Administration of VVcopTK-RR- (NCTNCT03724071) Click to edit Master title style Phase I (dose escalation completed) Administration schedule 1x106 to 3x109 pfu - 3 infusions optimization Arm A in 3 weeks (days 1, 8 and 15) Patients with 6 cohorts - C
Slide 46: BT-001 | Exciting Preclinical Data
BT-001 | Exciting Preclinical Data Click to edit Master title style Outstanding and long-lasting Strong abscopal effect Anti-CTLA4 Ab and GM-CSF anti-tumor activity in several (impact on distant accumulate in tumors with low tumor models lesions) systemic exposure i.t. injection CT26 Tumor BT-001 1E
Slide 47: Contact
C O N TA C T Lucie Larguier Director Investor Relations and Corporate Communication +33 6 7624 7227 larguier@transgene.fr 400 Boulevard Gonthier d’Andernach | Parc d’Innovation | CS80166 67405 Illkirch Graffenstaden Cedex | France Tél.: + 33 (0)3 88 27 91 21 | www.transgene.fr